所有图片(1)
About This Item
经验公式（希尔记法）:
C16H18FN3O2
CAS号:
分子量:
303.33
Beilstein:
8072099
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
药品控制
USDEA Schedule V
颜色
white to light brown
溶解性
DMSO: >15 mg/mL
储存温度
room temp
SMILES字符串
FC1=CC=C(CNC2=CC(N)=C(NC(OCC)=O)C=C2)C=C1
InChI
1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)
InChI key
PCOBBVZJEWWZFR-UHFFFAOYSA-N
基因信息
human ... KCNQ1(3784) , KCNQ2(3785) , KCNQ3(3786) , KCNQ4(9132) , KCNQ5(56479)
正在寻找类似产品? 访问 产品对比指南
生化/生理作用
瑞替加滨是一种 Kv7.2-7.5 钾通道激活剂； 抗惊厥药。
瑞替加滨（依佐加滨）是一种具有抗惊厥活性的 Kv7.2-7.5 （KCNQ2-5）神经元钾通道开放剂。
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 1
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Marrissa Martyn-St James et al.
Seizure, 21(9), 665-678 (2012-08-21)
Retigabine (RTG) is now approved in Europe and the US for the adjunctive treatment of partial-onset seizures in adults with epilepsy. To support submissions to EU reimbursement authorities, we explored its efficacy and tolerability relative to selected antiepileptic drugs (AEDs).
Dawn Craig et al.
PharmacoEconomics, 31(2), 101-110 (2013-01-24)
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of retigabine (GlaxoSmithKline) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of adults with partial-onset seizures in epilepsy, with and without
Piotr Czuczwar et al.
Pharmacological reports : PR, 62(2), 211-219 (2010-05-29)
Retigabine represents an antiepileptic drug possessing a completely different mechanism of action when compared to the existing classical and newer antiepileptic drugs. In the therapeutic range, retigabine enhances potassium currents, very likely via destabilization of a closed conformation or stabilization
G Blackburn-Munro et al.
CNS drug reviews, 11(1), 1-20 (2005-05-04)
Retigabine [D23129; N-(2-amino-4-(4-fluorobenzylamino)-phenyl)carbamic acid ethyl ester] is an antiepileptic drug with a recently described novel mechanism of action that involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels. These channels (primarily K(V)7.2/7.3) enable generation of the M-current, a subthreshold
Neil Brickel et al.
Epilepsia, 53(4), 606-612 (2012-03-21)
Retigabine (RTG; international nonproprietary name)/ezogabine (EZG; North American adopted name), a first-in-class antiepileptic drug (AED) that reduces neuronal excitability primarily by enhancing the activity of KCNQ2/3 (K(v)7.2/7.3) potassium channels, has recently been approved by the European Medicines Agency and the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门